NanoViricides is trading 7.9% higher in pre-market at $1.36, compared with the October 1 close of $1.26; no new company-specific announcement dated October 2 clearly explains the move.
- Recent coverage included the company’s annual report and reports that Phase II trials for NV-387 began enrollment in late September; both predate this alert.
- Biotech sector sentiment is negative in the supplied context, so it does not explain the stock’s gain.
- No trading volume or activity data was provided.